deltatrials
Completed PHASE1/PHASE2 NCT00104078

Study Evaluating MYO-029 in Adult Muscular Dystrophy

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Becker Muscular Dystrophy Facioscapulohumeral Muscular Dystrophy Limb-Girdle Muscular Dystrophy
Interventions MYO-029
Updated 6 times since 2017 Last updated: Dec 19, 2007 Started: Feb 28, 2005 Completion: Jan 31, 2007

Listed as NCT00104078, this PHASE1/PHASE2 trial focuses on Becker Muscular Dystrophy and Facioscapulohumeral Muscular Dystrophy and remains completed. Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Wyeth is now a wholly owned subsidiary of Pfizer
Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Baltimore, United States
  • • Boston, United States
  • • Columbus, United States
  • • Dallas, United States
  • • Kansas City, United States
  • • Rochester, United States
  • • Salt Lake City, United States
  • • St Louis, United States
  • • Washington D.C., United States